Abstract:
Background and Aims-Immunotherapy is a revolutionary treatment approach for rheumatoid
arthritis. However, based on our knowledge, the disease is not well studied. Understanding the
pathophysiology, possible diagnosis, and management interventions for rheumatoid arthritis is
crucial for improving the quality of life for individuals with the disease. This study was conducted
based on the PRISMA guidelines for review. Our data showed that immunotherapy has demon-
strated significant potential in the management of rheumatoid arthritis by specifically targeting
dysregulated immune responses implicated in the disease pathogenesis. TNF-α inhibitors, IL-6
receptor antagonists, B-cell depletion therapy, and JAK inhibitors have all shown efficacy in reduc-
ing inflammation and improving clinical outcomes in rheumatoid -arthritis patients. In addition,
by targeting the key immune pathways, immunotherapy demonstrated a substantial impact in
reducing the disease activity and slowing the progression of joint damage. Consequently, immu-
notherapy is a valuable therapeutic option for rheumatoid arthritis patients who do not respond
adequately to the traditional treatment modalities. As our understanding of the immunological
processes in rheumatoid arthritis deepens, further advances in immunotherapy are expected,
providing hope for more personalized and effective approaches to managing the chronic autoim-
mune disease.
